EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Nana Hou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, the Third Affiliated Hospital of Chongqing Medical University, Chongqing, China (N.H., Y.W., Q.Y., L.Z., W.…. Hauptthemen laut MEDLINE: Glioblastoma, Neoplastic Stem Cells, Brain Neoplasms, Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Science and Technology Major Project of Guangxi.
Abstract (Originalsprache)
Background
Glioblastoma stem cells (GSCs), a stem-like tumorigenic subpopulation within glioblastoma (GBM), exhibit remarkable self-renewal capacity and therapeutic resistance. Zinc finger BED domain-containing protein 1 (ZBED1), a dual-function transcription factor and SUMO E3 ligase, has been implicated in oncogenic processes across malignancies, its functional role and regulatory mechanisms in GSCs remain enigmatic.
Methods
Multimodal approaches including immunohistochemistry, immunoblotting, and immunofluorescence were employed to evaluate ZBED1 expression patterns in GSCs and clinical GBM specimens. Functional characterization utilized in vitro models (proliferation assays, tumor-sphere formation assays, limiting dilution analysis) complemented by in vivo orthotopic xenograft models. Mechanistic investigations integrated RNA sequencing, label-free proteomics, chromatin immunoprecipitation (ChIP), immunohistochemistry, and western blotting to delineate the EGFR/ZBED1 regulatory axis.
Results
We demonstrated that ZBED1 was significantly upregulated in GSCs and linked to unfavorable prognosis. Genetic ablation of ZBED1 significantly impaired GSC proliferation and self-renewal capacity, while extending survival in xenograft models. Mechanistically, EGFR-mediated ZBED1 phosphorylation at tyrosine residues Y160/Y513 enhanced ZBED1-UBC9 interaction, promoting SUMOylation-dependent protein stabilization. Remarkably, ZBED1 reciprocally sustained EGFR expression through transcriptional repression of the E3 ubiquitin ligase PARK2, establishing a self-reinforcing EGFR/ZBED1/PARK2 signaling circuit critical for GSC maintenance.
Conclusions
Our findings elucidate a novel EGFR/ZBED1 positive feedback loop that drives GSC propagation and tumorigenesis, highlighting ZBED1 as an attractive candidate for therapeutic targeting in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurosurgery, the Third Affiliated Hospital of Chongqing Medical University, Chongqing, China (N.H., Y.W., Q.Y., L.Z., W.Z., X.W., C.D., J.Y., S.C., J.J., Y.Z.).
- Jinfeng Laboratory, Chongqing, China (J.H., H.C.).
- State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing, China (J.H., H.C.).
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Science and Technology Major Project of Guangxi
Zitieren
APA
Hou, N., Wang, Y., You, Q., Zhang, L., Zhang, W., Wang, X., Deng, C., Yan, J., Cheng, S., Ji, J., Hou, J., Cui, H., & Zhang, Y. (2025). EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf215
Vancouver
Hou N, Wang Y, You Q, Zhang L, Zhang W, Wang X, et al. EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf215
BibTeX
@article{Hou2025,
author = {Hou, Nana and Wang, Yutao and You, Qiuxiang and Zhang, Lei and Zhang, Wenjia and Wang, Xinyi and Deng, Chunyan and Yan, Jiachuan and Cheng, Saiyu and Ji, Jianwen and Hou, Jianbing and Cui, Hongjuan and Zhang, Yundong},
title = {EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf215}
}
EUVIMED